Calidi Biotherapeutics Inc. reported a net loss of $5.2 million for the third quarter ended September 30, 2025, compared to a net loss of $5.1 million for the same period in 2024. A non-cash charge for deemed dividend on warrants increased the net loss attributable to shareholders to $10.8 million, while there was no such charge in the prior year period. Net loss per share, basic and diluted, was $2.21, down from $7.75 in the third quarter of 2024. Research and development expenses were $2.4 million, up from $2.2 million, and general and administrative expenses were $2.7 million, down from $3.1 million in the comparable period of 2024. The company had approximately $10.4 million in cash at the end of the quarter. Calidi raised $6.9 million in gross proceeds from an underwritten public offering, bringing total gross proceeds in 2025 to $23.0 million. Key business developments included new data presentations on CLD-401, further expansion of the RedTail platform, and the establishment of a Scientific Advisory Board.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Calidi Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-022349), on November 13, 2025, and is solely responsible for the information contained therein.
Comments